Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37210576)

  • 1. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.
    Chen J; Hong JH; Huang Y; Liu S; Yin J; Deng P; Sun Y; Yu Z; Zeng X; Xiao R; Chan JY; Guan P; Wang Y; Wang P; Liu L; Wen S; Yu Q; Ong CK; Teh BT; Xiong Y; Tan J
    Mol Cancer; 2023 May; 22(1):85. PubMed ID: 37210576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAPRE3 as an epigenetic target of EZH2 restricts ovarian cancer proliferation in vitro and in vivo.
    Zhang Y; Liu F; Zheng J; Jiang K; Ai H; Liu L; Mao D
    Exp Cell Res; 2024 Feb; 435(1):113913. PubMed ID: 38199479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2.
    Chen XJ; An N
    J Cell Mol Med; 2021 Jan; 25(1):37-46. PubMed ID: 33336896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
    Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
    Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
    Özeş AR; Pulliam N; Ertosun MG; Yılmaz Ö; Tang J; Çopuroğlu E; Matei D; Özeş ON; Nephew KP
    Oncogene; 2018 Jun; 37(26):3589-3600. PubMed ID: 29576612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.
    Yu X; Wang J; Gong W; Ma A; Shen Y; Zhang C; Liu X; Cai L; Liu J; Wang GG; Jin J
    Oncogene; 2023 Mar; 42(13):994-1009. PubMed ID: 36747009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
    Mu W; Starmer J; Yee D; Magnuson T
    Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The noncanonical role of EZH2 in cancer.
    Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
    Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The deletion of the protein phosphatase 1 regulator NIPP1 in testis causes hyperphosphorylation and degradation of the histone methyltransferase EZH2.
    Ferreira M; Verbinnen I; Fardilha M; Van Eynde A; Bollen M
    J Biol Chem; 2018 Nov; 293(47):18031-18039. PubMed ID: 30305391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of EZH2 in cancer and its inhibitors.
    Liu Y; Yang Q
    Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycomb Repressive Complex 2 in Oncology.
    Guo Y; Yu Y; Wang GG
    Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
    Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
    Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects.
    Xu S; Xu Y; Yin M; Zhang S; Liu P; Koroleva M; Si S; Little PJ; Pelisek J; Jin ZG
    Theranostics; 2018; 8(11):3007-3021. PubMed ID: 29896299
    [No Abstract]   [Full Text] [Related]  

  • 17. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
    Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
    Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of Ezh2 function remodels the DNA replication initiation landscape.
    Prorok P; Forouzanfar F; Murugarren N; Peiffer I; Charton R; Akerman I; Méchali M
    Cell Rep; 2023 Apr; 42(4):112280. PubMed ID: 36995935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.
    Anwar T; Gonzalez ME; Kleer CG
    Am J Pathol; 2021 May; 191(5):774-783. PubMed ID: 33556366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.
    Wan L; Xu K; Wei Y; Zhang J; Han T; Fry C; Zhang Z; Wang YV; Huang L; Yuan M; Xia W; Chang WC; Huang WC; Liu CL; Chang YC; Liu J; Wu Y; Jin VX; Dai X; Guo J; Liu J; Jiang S; Li J; Asara JM; Brown M; Hung MC; Wei W
    Mol Cell; 2018 Jan; 69(2):279-291.e5. PubMed ID: 29351847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.